Reticuloendothelial Cell Function in a‐Methyldopa‐Induced Hemolytic Anemia
- 1 October 1983
- journal article
- research article
- Published by Wiley in Vox Sanguinis
- Vol. 45 (4) , 278-287
- https://doi.org/10.1111/j.1423-0410.1983.tb01915.x
Abstract
Two patients having .alpha.-methyldopa [for control of hypertension]-induced hemolytic anemia were followed sequentially using an in vitro assay of autologous monocyte-macrophage activity to determine if their RES function was abnormal and thus could be related to the mechanism of lysis. RES function was evaluated while the patients were actively hemolyzing and during remission, following discontinuance of the drug. RES activity apparently is normal in patients having hemolytic anemia due to .alpha.-methyldopa administration. Also, following cessation of drug therapy, the patients'' IgG-coated red cells interacted significantly for a prolonged period (4-5 mo.) with autologous or normal allogeneic monocyte-macrophages. This was associated with a concurrent reticulocytosis and indicates a persistent low-level hemolytic phase throughut this period, even though Hb and hematocrit values remained within the normal ranges. Although levels of IgG sensitizing the patients red cells were essentially constant during the hemolytic phase and when the patients were in complete remission, significant monocyte-macrophage activity was only evident during the hemolytic period. In an attempt to explain this phenomenon, it is postulated that hemolysis in patients receiving .alpha.-methyldopa is related to the interaction of drug with red cell membrane proteins which results in a variably expressed altered antigen which is recognized by autoantibody. The proper expression of the Fc portion of the Ig molecule to result in specific recognition by receptors on monocyte-macrophages depends upon the extent of the antigen alteration by .alpha.-methyldopa. if the drug does not result in appropriate antigen alteration, then, although autoantibody may still bind to the red blood cell, its Fc region is not readily recognized by monocyte-macrophages and little or no erythrophagocytosis occurs.This publication has 15 references indexed in Scilit:
- Role of IgM in Human Monocyte‐Mediated Target Cell Destruction in VitroScandinavian Journal of Immunology, 1982
- Autoimmune Hemolytic Anemia with Reticulocytopenia and Erythroid MarrowNew England Journal of Medicine, 1982
- A New Elution Procedure Using Chloroform, a Nonflammable Organic SolventVox Sanguinis, 1982
- Modulation of alpha-methyldopa binding to the erythrocyte membrane by superoxide dismutaseBiochemical and Biophysical Research Communications, 1980
- Methyldopa Inhibition of Suppressor-Lymphocyte FunctionNew England Journal of Medicine, 1980
- Annotation. AUTOANTIBODY FORMATION ASSOCIATED WITH METHYLDOPA (ALDOMET) THERAPYBritish Journal of Haematology, 1969
- Alpha-Methyldopa Red-Cell Antibody: Cross-Reaction or Forbidden Clones?New England Journal of Medicine, 1967
- The Nature of the Alpha-Methyldopa Red-Cell AntibodyNew England Journal of Medicine, 1967
- AUTOIMMUNE HÆMOLYTIC ANÆMIA ASSOCIATED WITH α-METHYLDOPA THERAPYThe Lancet, 1966
- THE ANTIBODY RESPONSE IN RABBITS TO PREVIOUSLY TOLERATED ANTIGENS*Annals of the New York Academy of Sciences, 1965